Vamorolone vs corticosteroid real-world experience: Comparisons of 2-year treatment with NorthStar UK Network and CINRG Duchenne Natural History Study


Topic:

Clinical Trials

Poster Number: Virtual

Author(s):

Jean Mah, MD, MS, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada, Paula R. Clemens, MD, University of Pittsburgh School of Medicine, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, Michela Guglieri, MD, John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle upon Tyne, UK., Edward Smith, MD, Duke University Hospital, Richard Finkel, MD, St. Jude Children’s Research Hospital, Memphis, TN, USA., Mar Tulinius, MD, Queen Silvia Children’s Hospital, Gothenburg, Sweden., Yoram Nevo, MD, Schneider Children’s Medical Center, Tel Aviv University, Tel Aviv, Israel., Monique Ryan, Dr, Murdoch Children's Research Institute, Richard Webster, MD, The Children’s Hospital at Westmead, Sydney, Australia., Diana Castro, MD, University of Texas Southwestern, Dallas, TX, USA., Nancy Kuntz, MD, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, USA., Craig McDonald, MD, UC Davis Health, Georgia Stimpson, MS, Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK., Deborah Ridout, MS, Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK., Vandana Ayyar-Gupta, PhD, Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK., Giovanniu Baranello, MD, Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK., Adnan Manzur, FRCPCH, Great Ormond Street Institute of Child Health, London, UK, Francesco Muntoni, MD, Great Ormond Street Institute of Child Health, London, UK, Leanne Ward, MD, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada., Heather Gordish-Dressman, PhD, Children’s National Hospital, Washington DC, USA., Eric Hoffman, PhD, AGADA Biosciences Inc., Utkarsh Dang, PhD, Carleton University, Ottawa, ON, Canada.

Objective: We report 2-year treatment period of vamorolone (VBP15-LTE) versus corticosteroid treatment data from the NorthStar UK (NSUK) Clinical Network and the CINRG Duchenne Natural History Study (DNHS).
Results: The mean TTSTAND, TTRW, and TTCLIMB velocities were not significantly different between the vamorolone-treated VBP-LTE (n=23) and group-matched corticosteroid-treated DNHS participants (n=75). As well, the 2-year change in mean total NSAA scores for vamorolone-treated participants (-0.61± 8.12 [CI -4.65, 3.43]; n=18) was similar to NSUK corticosteroid-treated participants (-0.39 ± 5.29 [CI -1.907, 1.132]; n=49). A relative risk analysis of NSAA scores showed no significant difference in the risk of losing a motor function between the two cohorts: NSUK participants lost 139/1734 functions while VBP15-LTE participants lost 26/335 functions (RR 1.033 [CI 0.691, 1.544]). Nonparametric maximum likelihood estimate of median time to reach a TTSTAND milestone of ?10 seconds for VBP15-LTE participants was >9.31 years (CI 7.51, Inf), for DNHS >9.31 years (CI 8.29, Inf), and for NSUK 9.55 years (CI 8.87, Inf).
Conclusions: Vamorolone showed a disease-modifying effect in boys with DMD, with maintenance of muscle strength and function similar to corticosteroid real-world data observed in the NSUK and DNHS cohorts over a 2-year treatment period.